EMEA-000499-PIP03-17
Key facts
| Active substance |
Veliparib
|
| Decision number |
EMEA-000499-PIP03-17
|
| PIP number |
EMEA-000499-PIP03-17
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of breast cancer
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
AbbVie Ltd
Tel. +44 (0)1628 925033 E-mail: paediatricteam@abbvie.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|